AbbVie gains as investors weigh stronger growth outlook and recent pipeline wins

AbbVie (ABBV) is up 6.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to improving confidence in AbbVie’s post-Humira growth story, supported by continued strength from Skyrizi and Rinvoq, a recent credit outlook improvement, and fresh momentum from its oncology pipeline. There does not appear to be one single same-day catalyst, so today’s jump likely reflects investors repricing a cluster of recent positives.

Details:

AbbVie’s first-quarter 2026 results showed revenue growth and strong sales from Skyrizi and Rinvoq, and the company raised its full-year adjusted earnings guidance.

A recent ratings outlook improvement highlighted expectations for continued revenue expansion, with immunology growth viewed as a key support for the business over the next two years.

AbbVie recently won U.S. approval for Decnupaz in an ultra-rare blood cancer, adding another commercial product to its oncology portfolio and marking an important antibody-drug conjugate milestone.

The company has also been adding to its regulatory and clinical news flow, including submissions tied to Skyrizi and Rinvoq and new hematology data presented in June, which may have reinforced a more bullish view of the pipeline.

Sources:

AbbVie, FDA, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ABBV Insider Trading Activity

$ABBV insiders have traded $ABBV stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.

Here’s a breakdown of recent trading of $ABBV stock by insiders over the last 6 months:

PERRY C SIATIS (EVP, GC AND SECRETARY) has made 0 purchases and 3 sales selling 18,668 shares for an estimated $4,375,549.
DAVID RYAN PURDUE (SVP, Controller) sold 5,230 shares for an estimated $1,221,518

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive ABBV Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$ABBV Hedge Fund Activity

We have seen 1,856 institutional investors add shares of $ABBV stock to their portfolio, and 1,978 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CHARLES SCHWAB INVESTMENT MANAGEMENT INC removed 12,202,446 shares (-48.5%) from their portfolio in Q1 2026, for an estimated $2,642,195,632
FISHER ASSET MANAGEMENT, LLC added 8,463,716 shares (+1347.0%) to their portfolio in Q1 2026, for an estimated $1,832,648,425
WELLINGTON MANAGEMENT GROUP LLP removed 8,028,867 shares (-53.8%) from their portfolio in Q1 2026, for an estimated $1,738,490,571
DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN removed 7,827,781 shares (-87.8%) from their portfolio in Q1 2026, for an estimated $1,694,949,419
CAPITAL RESEARCH GLOBAL INVESTORS added 5,846,586 shares (+23.0%) to their portfolio in Q1 2026, for an estimated $1,265,961,266
CARDANO RISK MANAGEMENT B.V. removed 4,908,260 shares (-90.1%) from their portfolio in Q1 2026, for an estimated $1,062,785,537
JPMORGAN CHASE & CO removed 4,141,493 shares (-7.3%) from their portfolio in Q4 2025, for an estimated $946,289,735

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ABBV Government Contracts

We have seen $309,850 of award payments to $ABBV over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

PROSTHETIC ORDER - IMPLANT ITEMS: $15,758
4568645077!NATRELLE TE SMOOTH 133S-MV-11-T: $9,109
PROSTHETICS:SURGICAL IMPLANTS BREAST RECONSTRUCTION: $8,468
4569321051!NATRELLE INSPIRA SCF 605CC BREAST IMPLAN: $4,014

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard. You can access data on government contracts through the Quiver Quantitative API government contracts endpoint.

$ABBV Congressional Stock Trading

Members of Congress have traded $ABBV stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $ABBV stock by members of Congress over the last 6 months:

REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 05/05.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$ABBV Price Targets

Multiple analysts have issued price targets for $ABBV recently. We have seen 10 analysts offer price targets for $ABBV in the last 6 months, with a median target of $254.5.

Here are some recent targets:

Gavin Clark-Gartner from Evercore ISI Group set a target price of $235.0 on 05/15/2026
David Amsellem from Piper Sandler set a target price of $298.0 on 05/14/2026
Vamil Divan from Guggenheim set a target price of $249.0 on 05/01/2026
Carter Gould from Cantor Fitzgerald set a target price of $240.0 on 04/30/2026
Terence Flynn from Morgan Stanley set a target price of $278.0 on 04/30/2026
Gary Nachman from Canaccord Genuity set a target price of $265.0 on 04/30/2026
Trung Huynh from RBC Capital set a target price of $260.0 on 02/25/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.